# 177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

> **NCT06880757** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ankara University** · enrollment: 10 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

## Interventions

- **OTHER:** Radionuclide treatment with Lu-177 FAPI

## Key facts

- **NCT ID:** NCT06880757
- **Lead sponsor:** Ankara University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880757, "177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06880757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*